New Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths
Haemonetics (NYSE: HAE) said a retrospective Emory University study of 1,623 patients using its VASCADE MVP XL venous vascular closure system in large-bore electrophysiology procedures found median hemostasis of 2 minutes, 92.5% same-day discharge (median 3.5 hours), and 1.2% overall vascular complications with no surgical interventions. The FDA expanded labeling in March 2026.
How this was made
The 30-second read
Why it matters
Today’s PR adds a large real-world retrospective cohort (1,623 patients) reporting rapid hemostasis, same-day discharge metrics, and low vascular complication rates, which can support clinician confidence and commercial adoption.
Market read
Clinical evidence update for HAE’s electrophysiology closure product, likely more supportive than market-moving without new regulatory, financial, or competitive displacement details.
What to watch
Adoption depends on procedure mix, operator learning curve, and reimbursement dynamics; the PR does not provide comparative outcomes versus competing closure systems or utilization/market-share data.
Background
Haemonetics’ VASCADE MVP XL venous vascular closure system received expanded FDA labeling in March 2026 for larger-bore sheath procedures (10-14F ID, up to 17F OD).
Ticker impact
Haemonetics published a retrospective cohort of 1,623 patients showing VASCADE MVP XL rapid hemostasis and 1.2% vascular complications in large-bore electrophysiology procedures.
Near-term impact likely limited unless accompanied by incremental commercial traction signals; could modestly support sentiment around Interventional Technologies.
This is clinical evidence and promotional PR rather than a new FDA action or financial disclosure. However, it is a large cohort and aligns with previously expanded labeling, which can reduce adoption friction.
Market effects
Reinforces evidence standards for electrophysiology vascular closure devices, potentially raising competitive expectations for real-world outcomes in large-bore sheath use.
Primarily US-focused evidence (Emory University) that may influence US electrophysiology practice patterns.
Could support broader international adoption if the evidence is used in global clinical and reimbursement discussions.
Counterpoint
Because the study is single-center, retrospective, and funded by Haemonetics, the market may discount it versus independently validated, multicenter randomized evidence.
Key entities
- companyHaemonetics Corporation
NYSE-listed medical technology company marketing the VASCADE MVP XL venous vascular closure system.
- productVASCADE MVP XL
Extravascular venous vascular closure system used after electrophysiology venous access procedures, including PFA and LAAC.
- institutionEmory University
Conducted the single-center retrospective study evaluating real-world outcomes.
- regulatorU.S. Food and Drug Administration (FDA)
Approved expanded labeling for VASCADE MVP XL in March 2026.
